tbuckley/cabot-search huggingface dataset:
Three patients with advanced cutaneous angiosarcoma treated with eribulin: investigation of serum soluble CD163 and chemokine (C-X-C motif) ligand 10 as possible biomarkers predicting the biological behaviour of angiosarcoma
Authors: T. Fujimura, Y. Sato, Y. Kambayashi, K. Tanita, A. Tsukada, H. Terui, A. Hashimoto, S. Aiba
Journal: British Journal of Dermatology (2018)

Cutaneous angiosarcoma (CAS) is a highly aggressive vascular tumour that recurs locally and metastasizes early. Although chemoradiotherapy with taxanes shows a high response rate with prolonged survival, second‐line therapy for advanced CAS remains contentious. This report describes three patients with advanced CAS treated with eribulin. In addition, we investigated serum soluble (s)CD163, chemokine (C‐X‐C motif) ligand 10 (CXCL10) and chemokine (C‐C motif) ligand 2 levels at several time points of tumour progression in these patients, revealing serum levels of sCD163 and CXCL10 as potential biomarkers for progression of CAS.
Health Care Provider Counseling for Weight Loss Among Adults with Arthritis and Overweight or Obesity — United States, 2002–2014
Authors: Dana Guglielmo, Jennifer M. Hootman, Louise B. Murphy, Michael A. Boring, Kristina A. Theis, Brook Belay, Kamil E. Barbour, Miriam G. Cisternas, Charles G. Helmick
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

In the United States, 54.4 million adults report having doctor-diagnosed arthritis (1). Among adults with arthritis, 32.7% and 38.1% also have overweight and obesity, respectively (1), with obesity being more prevalent among persons with arthritis than among those who do not have arthritis (2). Furthermore, severe joint pain among adults with arthritis in 2014 was reported by 23.5% of adults with overweight and 31.7% of adults with obesity (3). The American College of Rheumatology recommends weight loss for adults with hip or knee osteoarthritis and overweight or obesity,* which can improve function and mobility while reducing pain and disability (4,5). The Healthy People 2020 target for health care provider (hereafter provider) counseling for weight loss among persons with arthritis and overweight or obesity is 45.3%.† Adults with overweight or obesity who receive weight-loss counseling from a provider are approximately four times more likely to attempt to lose weight than are those who do not receive counseling (6). To estimate changes in the prevalence of provider counseling for weight loss reported by adults with arthritis and overweight or obesity, CDC analyzed National Health Interview Survey (NHIS) data.§ Overall, age-standardized estimates of provider counseling for weight loss increased by 10.4 percentage points from 2002 (35.1%; 95% confidence interval [CI] = 33.0-37.3) to 2014 (45.5%; 95% CI = 42.9-48.1) (p<0.001). Providing comprehensive behavioral counseling (including nutrition, physical activity, and self-management education) and encouraging evidence-based weight-loss program participation can result in enhanced health benefits for this population.
TCTAP A-010 Association of Brain Amygdalar Activity with Plaque Burden and Vulnerability in Coronary Artery
Authors: Eun Jin Park, Jae Seon Eo, Won Young Jang, Jin Oh Na, Cheol Ung Choi, Hong Euy Lim, Eung Ju Kim, Seung-Woon Rha, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh, Jin Won Kim
Journal: Journal of the American College of Cardiology (2018)
Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016
Authors: Dirk Mentzer, Doris Oberle, Brigitte Keller-Stanislawski
Journal: Eurosurveillance (2018)

Background and aimIn January 2013, a novel vaccine against Neisseria meningitidis serogroup B, the multicomponent meningococcal serogroup B vaccine (4CMenB), was approved by the European Medicines Agency. We aimed to evaluate the safety profile of this vaccine. Methods: All adverse events following immunisation (AEFI) reported from Germany since the vaccine's launch in Germany in November 2013 through December 2016 were reviewed and analysed. Results: Through December 2016, a total of 664 individual case safety reports (ICSR) notifying 1,960 AEFI were received. A majority of vaccinees for whom AEFI were reported were children 2 to 11 years of age (n = 280; 42.2%) followed by infants and toddlers aged 28 days to 23 months (n = 170; 25.6%). General disorders and administration site conditions was the System Organ Class (SOC) with the majority of AEFI (n = 977; 49.8%), followed by nervous system disorders (n = 249; 12.7%), and skin and subcutaneous tissue disorders (n = 191; 9.7%). Screening of patient records for immune-mediated and neurological diseases did not raise any safety signal in terms of an increased proportional reporting ratio (PRR). Conclusions: The safety profile described in the Summary of Product Characteristics, in general, is confirmed by data from spontaneous reporting. No safety concerns were identified.
Discovery of a novel core inhibitor EP-027367 with potent antiviral activity both in vitro and in a humanized mouse model
Authors: M. Vaine, S. Clugston, J. Kass, X. Gao, H. Cao, W. Li, X. Peng, L. Jiang, K. Daniels, Y.-L. Qiu, Y.S. Or, K. Lin
Journal: Journal of Hepatology (2018)
Response to Trametinib of a Pulmonary Langerhans Cell Histiocytosis Harboring a <i>MAP2K1</i> Deletion
Authors: Gwenaël Lorillon, Fanelie Jouenne, Barouyr Baroudjian, Constance de Margerie-Mellon, Laetitia Vercellino, Véronique Meignin, Celeste Lebbe, Robert Vassallo, Samia Mourah, Abdellatif Tazi
Journal: American Journal of Respiratory and Critical Care Medicine (2018)
A phase 3b, open-label, randomized, pragmatic study of glecaprevir/pibrentasvir +/− ribavirin (RBV) for HCV genotype 1 subjects who previously failed an NS5A Inhibitor + sofosbuvir (SOF) therapy
Authors: A. Lok, I. Willner, R. Reddy, M. Hassan, F. Hinestrosa, M. Shiffman, M. Sulkowski, R. Brown, G. Morelli, J. Peter, M.W. Fried, M. Vainorius, L. Michael, G. Wang, Y. Hu, J. Kort, D.R. Nelson
Journal: Journal of Hepatology (2018)
TCT-294 Long Term Outcome of Unprotected Left Main Coronary Artery Disease: Comparison between Coronary Artery Bypass Grafting (CABG) and Percutaneous Coronary Intervention (PCI) in Korean Single Center
Authors: Moo Hyun Kim, Kai Song, Jia Xin Li, Soo Jin Kim, Kyungil Park, Young-rak Cho
Journal: Journal of the American College of Cardiology (2018)
Effect of Systematic Physician Cross-checking on Reducing Adverse Events in the Emergency Department
Authors: Yonathan Freund, Hélène Goulet, Judith Leblanc, Jérôme Bokobza, Patrick Ray, Maxime Maignan, Sabine Guinemer, Jennifer Truchot, Anne-Laure Féral-Pierssens, Youri Yordanov, Anne-Laure Philippon, Edwin Rouff, Ben Bloom, Marine Cachanado, Alexandra Rousseau, Tabassome Simon, Bruno Riou
Journal: JAMA Internal Medicine (2018)

Emergency departments (ED) are environments that are at high risk for medical errors. Previous studies suggested that the proportion of medical errors may decrease when more than 1 physician is involved.To reduce the proportion of medical errors by implementing systematic cross-checking between emergency physicians.This cluster randomized crossover trial includes a random sample of 14 adult patients (age ≥18 years) per day during two 10-day period in 6 EDs (n = 1680 patients) in France.Systematic cross-checking between emergency physicians, 3 times a day, which included a brief presentation of one physician's case to another, followed by the second physician's feedback to the first.Medical error in the ED, defined as an adverse event (either a near miss or a serious adverse event). The primary end point was identified using a 2-level error detection surveillance system, blinded to the strategy allocation.Among the 1680 included patients (mean [SD] age, 57.5 [21.7] years), 144 (8.6%) had an adverse event. There were 54 adverse events among 840 patients (6.4%) in the cross-check group compared with 90 adverse events among 840 patients (10.7%) in the standard care group (relative risk reduction [RRR], 40% [95% CI, 12% to 59%]; absolute risk reduction [ARR], 4.3%; number needed to treat [NNT], 24). There was also a significant reduction rate of near misses (RRR, 47% [95% CI, 15% to 67%]; ARR, 2.7%; NNT, 37) but not of the rate of preventable serious adverse events (RRR, 29% [95% CI, -18% to 57%]; ARR, 1.2%; NNT, 83).The implementation of systematic cross-checking between emergency physicians was associated with a significant reduction in adverse events, mainly driven by a reduction in near misses.ClinicalTrials.gov Identifier: NCT02356926.
The elevation of circulating fibroblast growth factor 23 without kidney disease does not increase cardiovascular disease risk
Authors: Eva-Maria Pastor-Arroyo, Nicole Gehring, Christiane Krudewig, Sarah Costantino, Carla Bettoni, Thomas Knöpfel, Sibylle Sabrautzki, Bettina Lorenz-Depiereux, Johanne Pastor, Tim M. Strom, Martin Hrabě de Angelis, Giovanni G. Camici, Francesco Paneni, Carsten A. Wagner, Isabel Rubio-Aliaga
Journal: Kidney International (2018)
Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia
Authors: Michelle L. Churchman, Maoxiang Qian, Geertruy te Kronnie, Ranran Zhang, Wenjian Yang, Hui Zhang, Tobia Lana, Paige Tedrick, Rebekah Baskin, Katherine Verbist, Jennifer L. Peters, Meenakshi Devidas, Eric Larsen, Ian M. Moore, Zhaohui Gu, Chunxu Qu, Hiroki Yoshihara, Shaina N. Porter, Shondra M. Pruett-Miller, Gang Wu, Elizabeth Raetz, Paul L. Martin, W. Paul Bowman, Naomi Winick, Elaine Mardis, Robert Fulton, Martin Stanulla, William E. Evans, Mary V. Relling, Ching-Hon Pui, Stephen P. Hunger, Mignon L. Loh, Rupert Handgretinger, Kim E. Nichols, Jun J. Yang, Charles G. Mullighan
Journal: Cancer Cell (2018)
P305By promoting cardiac regeneration FGF10 preserves cardiac remodeling and function after myocardial infarction
Authors: S Payan, F Hubert, R Sturny, R G Kelly, F Rochais
Journal: Cardiovascular Research (2018)

Purpose: To study sex-specific expression patterns of miR-29b and its target AKT-3 in the LV myocardium of AS patients, and of mice subjected to transverse aortic constriction (TAC) and after TAC release (de-TAC).Methods: The subjects of the study were AS patients of both sexes and male and female mice subjected to TAC (4 weeks) and de-TAC (1 week).LV expressions of miR-29 and AKT-3 were determined by qPCR.Primary fibroblasts were isolated from mouse LV.LV morph-functional changes were followed by echocardiography.Results: LV miR-29b was downregulated in male mice (fold-change ¼ 0.660.1*)while up-regulated in females (fold-change: 2.760.8*)after TAC.MiR-29b and its target AKT3 correlated negatively (r ¼ -0.52**)only in females.AKT3 mRNA levels correlated positively with the interventricular septum thickness (r¼0.57*),posterior wall thicknesses (r¼0.5**) and LV mass (r¼0.54**) in female, but not in males.Regression of LV hypertrophy after de-TAC was higher in females than in males (13.4 % vs 6.8%) and the LV expression of AKT3 was lower in in females than in males (7.361.3 vs 10.561.1*).Females subjected to oophorectomy presented after TAC higher LV levels of AKT3 compared to intact females (6.161.0 vs 3.260.2*).In cultured primary fibroblasts, the profibrotic effect of rTGF-beta mediated by miR-29b down-regulation was observed in cells obtained from males only.In female primary fibroblasts, oestrogens induced dose-dependent upregulation of miR-29 and down-regulation of AKT-3.Linear regression analysis revealed myocardial AKT-3 expression as a predictor of LV mass regression after AVR in AS women but not in men.Conclusion: Mir-29b and its target AKT-3 exhibit a sex-specific regulation in the LV under PO.AKT-3 overexpression is related with maladaptive hypertrophy in TAC-female mice and in AS women.These results provide insights on the molecular mechanisms involved in gender-related differences in cardiac remodelling.
Megakaryocyte Growth and Development Factor-Induced Proliferation and Differentiation Are Regulated by the Mitogen-Activated Protein Kinase Pathway in Primitive Cord Blood Hematopoietic Progenitors
Authors: Serge Fichelson, Jean-Marc Freyssinier, Françoise Picard, Michaela Fontenay-Roupie, Martine Guesnu, Mustapha Cherai, Sylvie Gisselbrecht, Françoise Porteu
Journal: Blood (1999)
TCTAP A-056 Impact of Increased High-sensitivity C-reactive Protein Level on 5-year Clinical Outcomes in Patients with Chronic Total Occlusion Lesion
Authors: Seung-Woon Rha, Jae Kyeong Byun, Byoung Geol Choi, Se Yeon Choi, Ahmed Mashaly, Yoonjee Park, Won Young Jang, Woo Hyeun Kim, Eun Jin Park, Jah Yeon Choi, Jin Oh Na, Cheolung Choi, Hong Euy Lim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh
Journal: Journal of the American College of Cardiology (2018)
P474Stable PET-reporter gene transfection of MSCs for in vivo long-term cell tracking in xenogeneic transplanted tissue engineered heart valves
Authors: K Zlabinger, D Lukovic, A Gugerell, J Winkler, A Spannbauer, M Emmert, S P Hoerstrup, M Gyoengyoesi
Journal: Cardiovascular Research (2018)

Results: Stereomicroscope and confocal imaging showed efficient Cre-meditated recombination near the intra-cardiac injection sites which was independent of the buffer osmolarity.Importantly, no Cre-mediated recombination was observed in the liver, kidney, lung, and spleen.Furthermore, cardiac ischemia did not influence the transduction efficiency of recombinant Cre protein via iTOP.Finally, activity assays determined the biological activity of Cre-YAP5SA and YAP5SA in vitro.Conclusions: Utilizing a novel methodology, we show efficient and local delivery of recombinant protein to the heart both under physiological and ischemic conditions.Future studies will focus on the delivery of the transcriptional regulator YAP5SA with the aim to promote the proliferative capacity of cardiomyocytes and augment cardiac regeneration after an ischemic insult.
Effect of a text message intervention to reduce hazardous drinking among injured patients discharged from a trauma ward: a randomized controlled trial
Authors: Sarah Sharpe, Bridget Kool, Robyn Whittaker, Arier C. Lee, Papaarangi Reid, Ian Civil, Matthew Walker, Vanessa Thornton, Shanthi Ameratunga
Journal: npj Digital Medicine (2018)

Screening and brief intervention for hazardous alcohol use in trauma care settings is known to reduce alcohol intake and injury recidivism, but is often not implemented due to resource constraints. Brief interventions delivered by mobile phone could overcome this challenge. This study aimed to evaluate the effect of a mobile phone text message intervention (YourCallTM) on hazardous drinkers admitted for an injury. The parallel two-group, single-blind, randomised controlled trial enrolled 598 injured patients aged 16-69 years identified as medium-risk drinkers at recruitment. The intervention group (n = 299) received 16 text messages incorporating brief intervention principles in the 4 weeks following discharge from hospital. Controls (n = 299) received usual care and one text message acknowledging participation in the trial. The primary outcome was the difference in hazardous alcohol use (assessed using AUDIT-C) between study groups at 3 months, with the maintenance of effect examined at 6 and 12 months' follow-up. Data were analysed using a mixed-effects model for repeated measures. Both groups had similar baseline features. Compared to controls, hazardous drinking was significantly lower in the intervention group at 3 months and maintained over the 12-month follow-up period (least squares mean difference in AUDIT-C scores: -0.322; 95% CI: -0.636, -0.008; p = 0.04). The intervention effect was similar among Māori (New Zealand's indigenous population) and non-Māori (interaction p = 0.59), and among younger (16-29 years) and older (30-69 years) patients (p = 0.77). The effectiveness of this intervention reflects the potential of low cost, scalable mobile health technologies to overcome common barriers in implementing alcohol harm reduction strategies following injury.
A New Treatment Modality for Rheumatoid Arthritis: Combined Photothermal and Photodynamic Therapy Using Cu<sub>7.2</sub>S<sub>4</sub> Nanoparticles
Authors: Yao Lu, Lihua Li, Zefeng Lin, Liping Wang, Lijun Lin, Mei Li, Yu Zhang, Qingshui Yin, Qi Li, Hong Xia
Journal: Advanced Healthcare Materials (2018)

Abstract Rheumatoid arthritis (RA) is a worldwide inflammatory disease that seriously threatens human health and needs more effective treatment approaches. Near infrared (NIR) light can efficiently penetrate inflamed joints affected by RA, so phototherapy, including photothermal therapy (PTT) and photodynamic therapy (PDT), may provide new opportunities. In this work, the unique Cu 7.2 S 4 nanoparticles (NPs) are prepared for RA treatment enlightened by the fact that copper (Cu)‐based nanomaterials can simultaneously serve as PTT agents and photosensitizers (for PDT). Meanwhile, Cu can promote ostogenesis and chondrogenesis. The Cu 7.2 S 4 NPs combined with NIR (808 nm, 1 W cm −2 ) irradiation not only achieve better bone preservation, including higher bone mineral density (BMD) and bone volume/total volume, but also inhibit inflamed synovial invasion, cartilage erosion, and expression of proinflammatory cytokines in vivo. Moreover, the Cu 7.2 S 4 NPs can effectively kill clinical pathogenic Staphylococcus aureus and Escherichia coli to prevent bacterial infection during intra‐articular injection. Therefore, the combined PTT and PDT using the multifunctional Cu 7.2 S 4 NPs could be a novel RA treatment modality with full potential.
Brief Report on the Detection of the EGFR T790M Mutation in Exhaled Breath Condensate from Lung Cancer Patients
Authors: Robert J. Smyth, Sinead M. Toomey, Alexander Sartori, Emer O'Hanrahan, Sinead D. Cuffe, Oscar S. Breathnach, Ross K. Morgan, Bryan T. Hennessy
Journal: Journal of Thoracic Oncology (2018)
MPs call for urgent ban on surgical mesh
Authors: Jacqui Wise
Journal: BMJ (2018)

MPs have called on the government to urgently suspend all mesh implant operations and for the National Institute for Health and Care Excellence (NICE) to bring forward guidelines on using mesh in stress related urinary incontinence from 2019 to 2018.

Leading the debate in the House of Commons on 19 April, Emma Hardy, MP for Kingston upon Hull West and Hessle, also called for pelvic floor physiotherapy to be offered to all new mothers as standard on the NHS, as happens in France.

She said, “Mesh was given to lots of young women following childbirth—many women still in their 30s—and it has left them feeling disabled. These women were injured. These women were ignored. These women …
P486TIMI grade flow 3 in STEMI patients loaded with ticagrelor in the field; a single centre experience
Authors: Z U Jan, TOM Kiernan, CIARA Cahill, IHSAN Ullah, MUNIR Ibrahim
Journal: Cardiovascular Research (2018)

divided into at least three cell populations: Classical monocytes (CM; CD14þþCD16-), intermediate monocytes (IM; CD14þþCD16þCCR2þ) and non-classical monocytes (NCM; CD14þCD16þþCCR2-).Purpose: The aim of this study was to analyze whether monocyte subset distribution is associated with 30-day survival in patients with AHF.Methods: We included 90 consecutive patients with AHF (33% with cardiogenic shock, 21% with acutely decompensated HF and 46% of patients suffered from AHF after cardiac arrest).Blood was taken at admission and after 72 hours and monocyte subset distribution was analyzed.Results: Mean age was 62.1 6 16.0, 76.7% of patients were male and median NT-proBNP levels were 4986 (1525 -23842) pg/mL.30-day survival was 64.4%.At admission, no association between monocyte subsets and outcome was seen.However on day 4, increased levels of IM (9.4 (4.0-13.8)% vs. 4.3 (2.1-7.9)%; p¼0.02, respectively).and lower levels of CM were predictive of 30-day mortality (86.8 (77.5 -88.9) % vs. 90.5 (84.3 -92.9), p¼ 0.02, respectively), while the NCM proportion was not associated with mortality.Risk of dying was increased 10.6-fold in the lowest tertile of CM and 9.5-fold in patients in the lowest IM tertile (p<0.05 for both).Conclusion: Circulating monocyte subsets are associated with 30-day mortality in patients with AHF requiring ICU admission.Activation status of the innate immune system as reflected by monocyte subset distribution may play a major role in pathophysiology and outcome in this patient cohort.
Alarming underutilisation of rehabilitation in athletes with anterior cruciate ligament reconstruction: four ways to change the game
Authors: Hege Grindem, Amelia JH Arundale, Clare L Ardern
Journal: British Journal of Sports Medicine (2018)

Alarming underutilisation of rehabilitation after ACL reconstruction (ACLR) was highlighted in a recent study.1 These Australian trends are not unique, but support the emerging realisation that athletes may be overtreated with ACLR surgery, but undertreated when it comes to rehabilitation. We use the term undertreated to describe insufficient rehabilitation—either because athletes are discharged too soon or because the rehabilitation content is inadequate.

Among non-elite athletes with ACLR, only 5% received rehabilitation1 that followed evidence-based guidelines2: ≥6 months’ rehabilitation, including agility and landing exercises, and a structured return to sport (RTS). Most athletes were undertreated: 45% (50 of 111) never saw a clinician after the third postoperative month and 70% (78 of 111) never did agility or landing exercises.1 When clinical practice does not follow evidence-based guidelines, we are not offering the best to our athletes.

Outcomes following ACLR are mainly dictated by the athlete, the rehabilitation clinician and the orthopaedic surgeon. And the rehabilitation clinician might be the central player in this trifecta.1 Almost a year …
Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy
Authors: Hirofumi Komaki, Tetsuya Nagata, Takashi Saito, Satoru Masuda, Eri Takeshita, Masayuki Sasaki, Hisateru Tachimori, Harumasa Nakamura, Yoshitsugu Aoki, Shin’ichi Takeda
Journal: Science Translational Medicine (2018)

NS-065/NCNP-01, an antisense oligonucleotide that enables exon 53 skipping in the dystrophin gene, showed a favorable safety profile and promising pharmacokinetics in 10 patients with Duchenne muscular dystrophy.
Neonatal Brain Injury and Timing of Neurodevelopmental Assessment in Patients With Congenital Heart Disease
Authors: Shabnam Peyvandi, Vann Chau, Ting Guo, Duan Xu, Hannah C. Glass, Anne Synnes, Kenneth Poskitt, A. James Barkovich, Steven P. Miller, Patrick S. McQuillen
Journal: Journal of the American College of Cardiology (2018)
PCSK9
Authors: Michael D. Shapiro, Hagai Tavori, Sergio Fazio
Journal: Circulation Research (2018)

Unknown 15 years ago, PCSK9 (proprotein convertase subtilisin/kexin type 9) is now common parlance among scientists and clinicians interested in prevention and treatment of atherosclerotic cardiovascular disease. What makes this story so special is not its recent discovery nor the fact that it uncovered previously unknown biology but rather that these important scientific insights have been translated into an effective medical therapy in record time. Indeed, the translation of this discovery to novel therapeutic serves as one of the best examples of how genetic insights can be leveraged into intelligent target drug discovery. The PCSK9 saga is unfolding quickly but is far from complete. Here, we review major scientific understandings as they relate to the role of PCSK9 in lipoprotein metabolism and atherosclerotic cardiovascular disease and the impact that therapies designed to inhibit its action are having in the clinical setting.